Sinonasal cancer, occupation, and tobacco smoking in European women and men

Mannetje, Andrea ’t; Kogevinas, Manolis; Luce, Danièle; Demers, Paul A.; Bégin, Denis; Bolm‐Audorff, Ulrich; Comba, Pietro; Gérin, Michel; Hardell, Lennart; Hayes, Richard B.; Leclerc, Annette; Magnani, Corrado; Merler, Enzo; Tobías, Aurelio; Boffetta, Paolo

doi:10.1002/(sici)1097-0274(199907)36:1<101::aid-ajim14>3.0.co;2-a

Cited by 109 publications

(48 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Treatmentmentioning

confidence: 99%

“…Although smoking has been implicated, studies have not confirmed it to be a significant etiologic factor [12]. Woodworkers are particularly at risk for developing adenocarcinoma of the ethmoid sinuses, which shows a striking male predominance (75%-90%) [12]. Bussi et al [8] reported in their study of 68 carpenters, with a minimum exposure to wood of 10 years, significant evidence of an elevated incidence of pavimentous metaplasia and deficit of immunoglobulin A. Sinonasal sarcomas have been correlated with a previous exposure to radiation and should be considered in the differential diagnosis in these individuals.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Management of paranasal sinus malignancy

Day

Beas²,

Schlosser³

et al. 2005

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Malignancies of the nasal cavity and paranasal sinuses represent a wide spectrum of histologies, tissues of origin, and anatomic primary sites. The inherent difficulty in generalizing treatment approaches is obvious, given the numerous variables associated with the broadly-based term, paranasal sinus malignancy (PNSCa). Nevertheless, the majority of epithelial and salivary malignancies of this region (ie, squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, sinonasal undifferentiated carcinoma, and esthesioneuroblastoma) require surgical intervention as part of any treatment regimen. Recent trends have broadened the indications for chemotherapeutic and radiotherapeutic options in the management of advanced PNSCa. Nonepithelial malignancies, including the wide variety of sarcomas arising in this region, most commonly require multimodality treatment including chemotherapy, radiation, and/or surgery for definitive treatment. Moreover, the proximity of the nasal cavity and paranasal sinuses to structures including the orbit, dura, brain, cranial nerves, and carotid arteries mandates careful radiologic and neurologic evaluations throughout the course of the disease. Surgical advances now permit complex tumor removal and reconstruction surrounding these structures resulting in functional and cosmetic improvements when compared to earlier techniques. However, additional clinical trials are necessary to systematically evaluate the locoregional control, organ-preservation strategies, and survival related to the variety of treatments currently available.

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Management of paranasal sinus malignancy

Day

Beas²,

Schlosser³

et al. 2005

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

show abstract

“…These include occupational exposure to wood dust and various chemical substances, such as nickel (during refining), but only for one rarely occurring sinonasal cancer subtype, the intestinal-type adenocarcinoma [4]. Interestingly, cigarette smoking, still a major risk factor for head and neck SCC, is only weakly associated with sinonasal cancer [5].…”

Section: Introductionmentioning

confidence: 99%

The presence of high-risk human papillomavirus (HPV) E6/E7 mRNA transcripts in a subset of sinonasal carcinomas is evidence of involvement of HPV in its etiopathogenesis

et al. 2015

View full text Add to dashboard Cite

The aim of the study was to investigate prevalence of high-risk human papillomavirus (HR-HPV) infection in sinonasal carcinomas by immunohistochemistry, in situ hybridization, and polymerase chain reaction, detecting p16(INK4a) protein (p16) expression and presence of both HPV DNA and HPV E6/E7 messenger RNA (mRNA). The study comprised 47 males and 26 females, aged 23-83 years (median 62 years), mostly (67 %) with a squamous cell carcinoma (SCC). Of the tumors, 53 % arose in the nasal cavity, 42 % in the maxillary sinus, and 5 % in the ethmoid complex. The follow-up period ranged 1-241 months (median 19 months). HPV16, HPV18, or HPV35 were detected in 18/73 (25 %) tumors, 17 SCCs, and 1 small cell neuroendocrine carcinoma. There was a strong correlation between results of HPV detection methods and p16 expression (p < 0.005). HPV-positive SCCs occurred more frequently in smokers (p = 0.04) and were more frequently p16-positive (p < 0.0001) and nonkeratinizing (p = 0.02), the latter occurring more commonly in nasal cavity (p = 0.025). Median survival for HPV-positive SCC patients was 30 months, while for HPV-negative SCC patients was 14 months (p = 0.23). In summary, we confirm that HR-HPV is actively involved in the etiopathogenesis of a significant subset of sinonasal SCCs. p16 may be used as a reliable surrogate marker for determination of HPV status also in sinonasal SCCs. Although we observed a trend toward better overall survival in HPV-positive SCCs, the prognostic impact of HPV status in sinonasal carcinomas needs to be elucidated by further studies.

show abstract

“…Certains auteurs suggè rent un rô le possible de la pollution atmosphé rique [2]. Enfin, comme pour les autres cancers ORL, le tabac augmente le risque de cancer nasosinusien [11]. Les sé ries les plus ré centes font é tat de taux de survie à cinq ans de 65 à 75 % [3].…”

Section: Cancers Rares Orl Cancers Des Fosses Nasales Et Des Sinusunclassified

A network of French experts for the management of rare ENT cancers (REFCOR)

Baujat

Hans

2008

Oncologie

View full text Add to dashboard Cite

Most ear-nose-throat (ENT) cancers are epidermoid carcinomas of the upper airways; their main risk factors are tobacco and alcohol consumption. Undifferentiated cancers of the nasopharynx are rare in Europe but endemic in other parts of the world. Apart from these two types, ENT malignant tumours are rare (less than 10% of all ENT cancers), both in terms of histology and as regards their location, which is a problem for any research on this topic. Employed treatments rely on poor evidence; most of the time, published series are retrospective, with small samples of patients and differing therapeutic methods. The aim of the planned network is to federate the working teams at a national scale so as to improve both epidemiologic knowledge and management of these diseases, and to generate research projects. This multidisciplinary network named REFCOR has been designed under the authority of several scientific societies with four important objectives: 1) the publication of national guidelines for the management of the four main groups of rare ENT cancers (malignant tumours of the salivary glands, malignant tumours of the nose and paranasal sinuses, malignant ear tumours, and malignant tumours of the upper airways excluding common epidermoid carcinomas); 2) the creation of a national database that will reference the cases and include epidemiologic, clinical, and histopathological data; 3) the implementation of regional reference centres for multidisciplinary consultation meetings resulting in an efficient national network; 4) the constitution of virtual tumour, serum, and cell banks, with standardized methods of collection and storage of the included patients' samples.

show abstract

Sinonasal cancer, occupation, and tobacco smoking in European women and men

Cited by 109 publications

References 18 publications

Management of paranasal sinus malignancy

Management of paranasal sinus malignancy

The presence of high-risk human papillomavirus (HPV) E6/E7 mRNA transcripts in a subset of sinonasal carcinomas is evidence of involvement of HPV in its etiopathogenesis

A network of French experts for the management of rare ENT cancers (REFCOR)

Contact Info

Product

Resources

About